Search

Your search keyword '"Campath (Medication) -- Evaluation -- Product/service Evaluations"' showing total 4 results
Start Over Descriptor "Campath (Medication) -- Evaluation -- Product/service Evaluations"
4 results on '"Campath (Medication) -- Evaluation -- Product/service Evaluations"'

1. TREATMENT OF SEVERE RESISTANT AUTOIMMUNE CYTOPENIAS WITH CAMPATH-1H

Author

Willis, F., Marsh, J, Bevan, D., Killick, S., Lucas, G., Griffiths, R., Ouwehand, W., Hale, G., Waldmann, H., and Gordon-Smith, E.

Subjects
Monoclonal antibodies -- Health aspects, Autoimmune diseases -- Care and treatment, Health, Campath (Medication) -- Evaluation -- Product/service Evaluations
Abstract

Background: Haemopoietic stem cell treatment has been proposed for severe resistant autoimmune cytopenias. An alternative and safer option may be the monoclonal antibody Campath-1H, which may reset the immune system [...]

Published
2001

2. AIDS-associated lymphomas are efficiently lysed by rituximab

Subjects
MabThera (Medication) -- Evaluation -- Product/service Evaluations, Campath (Medication) -- Evaluation -- Product/service Evaluations, Drug therapy, Evaluation, Complications and side effects, Non-Hodgkin lymphomas -- Drug therapy -- Complications and side effects, AIDS (Disease) -- Complications and side effects -- Drug therapy, Non-Hodgkin's lymphomas -- Drug therapy -- Complications and side effects
Abstract

2003 FEB 11 - (NewsRx.com & NewsRx.net) -- 'Rituximab (Mabthera) and alemtuzumab (Campath, Mabcampath) are non-conjugated IgG1 therapeutic monoclonal antibodies directed against the CD20 and CD52 surface antigens respectively. They [...]

Published
2003

3. Study reports success in treating refractory B-CLL, T-PLL

Subjects
Chronic lymphocytic leukemia -- Drug therapy, Business, Health, Health care industry, Campath (Medication) -- Evaluation -- Product/service Evaluations
Abstract

2003 JAN 14 - (NewsRx.com & NewsRx.net) -- Findings obtained from a compassionate use study of the humanized monoclonal antibody alemtuzumab (Campath/MabCampath) in patients with refractory B-cell chronic lymphocytic leukemia [...]

Published
2003

4. Combination of alemtuzumab, fludarabine phosphate effective, safe

Subjects
Chronic lymphocytic leukemia -- Drug therapy, Business, Health, Health care industry, Campath (Medication) -- Evaluation -- Product/service Evaluations, Fludara (Medication) -- Evaluation -- Product/service Evaluations
Abstract

2003 JAN 14 - (NewsRx.com & NewsRx.net) -- Efficacy and safety data from an ongoing phase II clinical trial of combination fludarabine phosphate (Fludara) and alemtuzumab (Campath/MabCampath) therapy (FluCam) for [...]

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results